Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation.
Anticoagulants
Apixaban
Atrial fibrillation
Direct oral anticoagulants
Safety
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
accepted:
15
01
2023
medline:
1
5
2023
pubmed:
31
1
2023
entrez:
30
1
2023
Statut:
ppublish
Résumé
Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To assess bleeding and thrombotic event rates for patients with AF that are prescribed apixaban and have a low versus normal body weight. We analyzed patients with AF prescribed apixaban from 2017 to 2020 with at least 12 months of follow-up. Patients were divided into low [< 60 kg (kg)] and normal (60-100 kg) weight cohorts. Bleeding and thrombotic event rates were compared. Poisson regression and Cox proportional hazard models were used to estimate adjusted adverse event rates. A total of 545 patients met inclusion criteria. In the unadjusted analysis, there was an increase in non-major bleeding events requiring an Emergency Department visit more often in the low versus normal weight cohort (10.8 versus 7.4 per 100 patient-years, p = 0.15). Thrombotic event rates also occurred more often in the lower versus normal weight cohort (2.4 versus 0.9 per 100 patient-years, p = 0.09). However, adjusted analysis found no statistically significant difference in bleeding or thrombotic events between low and normal weight cohorts. The adjusted hazard ratio for bleeding was similar between the two weight cohorts. The use of apixaban in low body weight patients was not associated with higher rates of bleeding or thrombotic events, compared to those with normal body weight, after adjusting for potential confounding covariates. Larger studies may offer further insight into the overall safety and efficacy of DOAC therapy in these patients.
Identifiants
pubmed: 36715882
doi: 10.1007/s11239-023-02777-y
pii: 10.1007/s11239-023-02777-y
doi:
Substances chimiques
Warfarin
5Q7ZVV76EI
apixaban
3Z9Y7UWC1J
Anticoagulants
0
Rivaroxaban
9NDF7JZ4M3
Pyridones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
680-684Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M (2015) Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 13(11):2012–2020. https://doi.org/10.1111/jth.13139
doi: 10.1111/jth.13139
pubmed: 26356595
Covert K, Branam DL (2020) Direct-acting oral anticoagulant use at extremes of body weight: literature review and recommendations. Am J Health Syst Pharm 77(11):865–876. https://doi.org/10.1093/ajhp/zxaa059
doi: 10.1093/ajhp/zxaa059
pubmed: 32426845
Lee SR, Choi EK, Park CS, Han KD, Jung JH, Oh S, Lip GYH (2019) Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol 73(8):919–931. https://doi.org/10.1016/j.jacc.2018.11.051
doi: 10.1016/j.jacc.2018.11.051
pubmed: 30819360
Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Iorio A, Lopes RD, Garcia D (2017) Crowther MA Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 15(7):1322–1333. https://doi.org/10.1111/jth.13701
doi: 10.1111/jth.13701
pubmed: 28407368
De Caterina R, Lip GYH (2017) The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol 106(8):565–572. https://doi.org/10.1007/s00392-017-1102-5
doi: 10.1007/s00392-017-1102-5
pubmed: 28396988
Barakat A, Jain S, Masri A et al (2021) Outcomes of direct oral anticoagulants in Atrial Fibrillation Patients across different body Mass Index categories. J Am Coll Cardiol 7(5):649–658. https://doi.org/10.1016/j.jacep.2021.02.002
doi: 10.1016/j.jacep.2021.02.002
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694. doi: https://doi.org/10.1111/j.1538-7836.2005.01204.x
doi: 10.1111/j.1538-7836.2005.01204.x
pubmed: 15842354
Park CS, Choi EK, Kim HM, Lee SR, Cha MJ, Oh S (2017) Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm. 14:501–507. https://doi.org/10.1016/j.hrthm.2016.12.036
doi: 10.1016/j.hrthm.2016.12.036
pubmed: 28042092
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330–393. https://doi.org/10.1093/eurheartj/ehy136
doi: 10.1093/eurheartj/ehy136
pubmed: 29562325